Klow vs Glow Peptide: What Changes When You Add KPV

The difference between glow and klow is one compound and one letter. GLOW is GHK-Cu, BPC-157 and TB-500 in a 70 mg vial. KLOW is the same three, in the same milligrams, plus 10 mg of KPV in an 80 mg vial. The K is the KPV, and that is the entire distinction.

That makes the comparison narrower and more answerable than most peptide comparisons, because the two blends share an identical 50 mg of GHK-Cu, which is the component that dominates both by mass. Whatever either blend does for skin, it does with the same amount of the same copper peptide. The question is not which is stronger. It is whether 10 mg of a tripeptide with no human data, and the different dosing shape that comes with it, is worth the extra vial size and the extra money.

This page puts the two side by side on composition, dosage, cycle length and cost per cycle, then sets out which one fits which goal. The blends have their own pages, GLOW and KLOW, each with its own dosage chart.

Klow vs Glow: The Side-by-Side

Two rows deserve a second look. The GHK-Cu share falls from 71 percent to 62.5 percent, but only because the denominator grew; the numerator is 50 mg in both. And the reconstitution volumes differ by convention rather than necessity. The charts in circulation put GLOW in 3 mL and KLOW in 2 mL, which is why the same "10 units" means 2.33 mg on one page and 4 mg on the other. That is the single most common source of confusion between the two, and it is purely a units problem.

What KPV Actually Adds

KPV is lysine-proline-valine, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. It is three amino acids long, which makes it one of the smallest compounds sold in this category, and its published record is mostly mouse colitis and inflammation models with some cell-culture work on skin and mucosal tissue. When FDA review staff prepared their evidence summary for the 2026 compounding advisory committee, they reported an absence of human exposure data for it. The KPV guide covers what is and is not known in detail.

The working hypothesis behind including it is that it brings an anti-inflammatory and gut-barrier element to a blend otherwise aimed at skin and tissue repair. That is a reasonable hypothesis and it is not a finding. No study has tested KPV alongside the other three, and the same caveat that applies to GLOW applies with one more compound attached to KLOW: nothing in the literature has evaluated either mixture.

What can be stated precisely is the amount. KPV is 12.5 percent of an 80 mg KLOW vial, so a 4 mg draw carries 500 mcg of it and a loading week at five draws carries 2.5 mg. Whether that is a meaningful exposure is not answerable from the published work, because there is no human dose response data for KPV to compare it against.

Dosage Differences, Worked Out

The two protocols look different on paper and land closer together than they look. Here is what a week on each delivers, per component, using the schedule most often reported for each blend.

A GLOW week and a KLOW loading week deliver GHK-Cu and BPC-157 amounts within about seven percent of each other. Anyone choosing between the blends on the assumption that KLOW is a heavier protocol is choosing on a number that is not there. What genuinely differs is shape. GLOW runs one flat phase, seven injections a week, for about four weeks, and then stops because the vial is empty. KLOW runs a front-loaded four weeks and then drops to roughly a third of that for another eight, which is why its reported cycle is two to three times as long.

The maintenance column is the one that changes the comparison most. At 6 mg of blend a week, KLOW maintenance delivers 3.75 mg of GHK-Cu, which is below the 1 to 2 mg per injection convention on three injections a week only if you look at it per week rather than per draw; per draw it is 1.25 mg, squarely inside it. That is a phase with no GLOW equivalent in the charts in circulation, and a researcher who wants a long run at a low steady amount is describing the KLOW maintenance protocol whether they call it that or not.

On copper, both loading schedules deliver roughly 2 mg a week subcutaneously, since GHK-Cu is about 16 percent copper by mass. The dietary reference intake is 0.9 mg a day, so neither is a large amount against dietary scale, but injected copper bypasses the intestinal regulation the dietary figure assumes. That is the main argument for keeping the off-cycle in both protocols, and the GHK-Cu injection dosage page works it through.

Cost Per Cycle

Per vial the two are close. Per cycle they are not, because the reported cycles are different lengths. The figures below use the Ascension shop listings the Bureau checked in the first week of September 2026, which are the only listings that itemised the components of both blends.

So KPV costs about $10 at the vial level and KLOW is marginally cheaper per milligram, $1.50 against $1.57. The real financial difference is not the KPV. It is that a KLOW protocol is a twelve-week commitment with a second vial in it, and a GLOW protocol is a four-week one that ends when the vial does. For a researcher who has not run either before, the smaller commitment is the one that answers the question at lower cost.

Two caveats on the pricing. These are one vendor's listings on one week, and the KLOW figure was a shop-page price against a regular $199.99, so the gap can look very different at another vendor or another time. And the leftover 32 mg is not waste if a second cycle follows, but a reconstituted vial is generally planned for use within about four weeks refrigerated, so a maintenance vial reconstituted with 2 mL will outlast that window. Some researchers reconstitute the second vial and accept the discard, and some buy a GLOW vial for the maintenance phase instead, which works because the maintenance phase is where the KPV content is smallest anyway.

Which One Fits Which Goal

Because the evidence cannot rank them, the useful question is fit. These are descriptions of what each blend contains and how it is run, not recommendations.

The last row of that table is the one most worth acting on. If KPV is genuinely wanted but not in every draw, buying GLOW and a separate KPV vial costs a little more in handling and gives back the thing a blend permanently removes, which is the ability to change one component without changing all of them. That option does not appear on any vendor's product page because no vendor sells it as a product.

One more point that applies to both and is easy to miss. The GHK-Cu in each blend is 50 mg and the single-compound convention is 1 to 2 mg per injection, so a standard draw of either lands inside the usual GHK-Cu range while delivering BPC-157 and TB-500 at amounts that would be considered low if those compounds were run alone. Both blends are, in practical terms, GHK-Cu protocols with two or three other peptides riding along. The GHK-Cu guide is the page that matters most for understanding what either one is mostly doing.

Evidence and Status, Stated Once

Neither blend has been studied. For the components: GHK-Cu has two controlled human trials, both topical; BPC-157 has a large rodent literature and no published human trials; TB-500 is sold as a fragment of thymosin beta-4, and the human phase 2 data belongs to the full protein rather than the fragment; KPV has mouse and cell data, with no human studies found in FDA's 2026 review. On regulatory status, BPC-157 was removed from FDA's Category 2 list in April 2026 and remains under Pharmacy Compounding Advisory Committee review; it is not currently compoundable. Injectable GHK-Cu was moved out of Category 2 in the same action and is scheduled for a later committee review. Everything on this page describes research compounds and what is reported about them.

Where to Buy Glow and Klow

Disclosure. Links in this section may earn the Bureau a commission at no additional cost to the reader. The method is on the vendor scorecard page. Prices and compositions are as the vendor displayed them when the Bureau checked.

Whichever blend and whichever vendor, run the vendor's own stated milligrams through the calculator rather than assuming the standard format. Apollo's KLOW is 75 mg rather than 80, which moves every row in both dosage charts, and vendors ship GLOW at sizes other than 70 mg too. Nothing here is medical advice; these are research compounds and the Bureau does not advise anyone on using them.

Frequently Asked Questions

What is the difference between klow and glow peptide?

One compound. GLOW is GHK-Cu, BPC-157 and TB-500, normally 50 mg, 10 mg and 10 mg in a 70 mg vial. KLOW is those same three in the same amounts plus 10 mg of KPV, which makes an 80 mg vial and a 5:1:1:1 ratio instead of 5:1:1. Nothing else changes: the GHK-Cu content is 50 mg in both, so the skin component that dominates each blend is identical. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone and it is included for an anti-inflammatory and gut-barrier element. Both are sold for research use and neither is an approved medicine.

Is klow or glow better?

Neither has been tested, so better is not something the evidence can settle. What can be settled is fit. If the goal is skin and appearance alone, the 10 mg of KPV in KLOW adds cost and a fourth compound with no human data for something outside that goal, and GLOW covers it with an identical 50 mg of GHK-Cu. If there is an inflammatory or gut element in the picture, KPV is the only reason either blend addresses it, and KLOW is the one that does. A researcher who wants KPV occasionally rather than in every draw is better served buying GLOW and a separate KPV vial, because a blend locks the ratio permanently.

Do klow and glow use the same dosage?

The protocols differ on paper and converge in practice. GLOW is usually reported at 10 units daily from a 70 mg vial in 3 mL, which is 2.33 mg of blend and 1.67 mg of GHK-Cu, giving 11.7 mg of GHK-Cu a week. KLOW is usually reported at 10 units five days a week from an 80 mg vial in 2 mL, which is 4 mg of blend and 2.5 mg of GHK-Cu, giving 12.5 mg a week. The weekly GHK-Cu and BPC-157 amounts are within about 7 percent of each other. What genuinely differs is the shape: GLOW runs one flat phase for about four weeks, KLOW runs a loading phase and then a lower maintenance phase over eight to twelve.

What does KPV add to the klow blend?

KPV is lysine-proline-valine, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. The published work is mostly mouse colitis and inflammation models with some cell-culture data on skin and mucosa, and FDA review staff told the compounding advisory committee in 2026 that they found no human studies of it. The working hypothesis behind putting it in the vial is that it adds an anti-inflammatory and gut-barrier element to a blend otherwise aimed at skin and tissue repair. At 10 mg of an 80 mg vial it is 12.5 percent of the mass, and a standard 4 mg draw carries 500 mcg of it.

Which costs more per cycle, klow or glow?

Per vial they are close and per cycle they are not, because the cycles are different lengths. On the Ascension shop listings the Bureau checked in the first week of September 2026, GLOW 70mg was $110 and KLOW 80mg was $120, so KPV adds about $10 to the vial and KLOW is marginally cheaper per milligram at $1.50 against $1.57. A reported GLOW cycle is one vial over about four weeks, roughly $110. A reported twelve-week KLOW cycle needs a loading vial plus part of a second for maintenance, so about $240 with around 32 mg left over. Per week on cycle that works out slightly cheaper for KLOW, with a larger amount committed upfront.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.